Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Depreciation & Amortization (CF) (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Depreciation & Amortization (CF) for 13 consecutive years, with $392000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) rose 7.99% to $392000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $1.5 million, a 37.41% increase, with the full-year FY2025 number at $1.5 million, up 37.41% from a year prior.
  • Depreciation & Amortization (CF) was $392000.0 for Q4 2025 at Madrigal Pharmaceuticals, up from $358000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $392000.0 in Q4 2025 to a low of $89000.0 in Q2 2021.
  • A 5-year average of $200050.0 and a median of $132000.0 in 2022 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): decreased 22.61% in 2021, then skyrocketed 155.63% in 2024.
  • Madrigal Pharmaceuticals' Depreciation & Amortization (CF) stood at $106000.0 in 2021, then grew by 21.7% to $129000.0 in 2022, then rose by 10.08% to $142000.0 in 2023, then surged by 155.63% to $363000.0 in 2024, then rose by 7.99% to $392000.0 in 2025.
  • Per Business Quant, the three most recent readings for MDGL's Depreciation & Amortization (CF) are $392000.0 (Q4 2025), $358000.0 (Q3 2025), and $377000.0 (Q2 2025).